https://www.selleckchem.com/pr....oducts/wnt-agonist-1
5bpm (95% CI -8.0, -1.0; p = 0.013). The mean (SE) changes in 6MWT distance and HR difference during the 6MWT were 16.3 (10.8) meters and 2.3 (3.7) bpm, respectively. Ivabradine therapy did not result in greater physical activity. TEAEs were reported in 11 (36.7%) patients. These data support ivabradine use in African American patients with HF with reduced ejection fraction who meet typical treatment criteria. ClinicalTrials.gov identifier, NCT03456856. ClinicalTrials.gov identifier, NCT03456856. The homeostatic euthyroid set poin